Format

Send to

Choose Destination
Thromb Res. 2007;121(2):159-62. Epub 2007 May 29.

Cystic fibrosis heterozygotes do not have increased platelet activation.

Author information

1
Department of Physiology and Biochemistry, University of Copenhagen, The Faculty of Life Sciences, Frederiksberg C, Denmark.

Abstract

INTRODUCTION:

We have previously demonstrated platelet hyperreactivity in cystic fibrosis (CF) patients. Carriers of one CF mutation (heterozygotes) have been shown to have abnormalities related to the presence of only one-half the normal amount of CF transmembrane conductance regulator protein. Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier.

MATERIALS AND METHODS:

We used highly sensitive assays of platelet activation to assess the difference between 16 CF heterozygotes and 16 age- and sex-matched healthy controls without CF mutations.

RESULTS:

We found no difference in platelet activation between CF heterozygotes and controls.

CONCLUSIONS:

The 50% reduction in the CF transmembrane conductance regulator protein in heterozygotes is insufficient to cause platelet activation.

PMID:
17532368
DOI:
10.1016/j.thromres.2007.04.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center